estramustine

also known as estramustine phosphate sodium · estramustine phosphate · EMP · NSC-89199

Developed for: prostate cancer · breast cancer · prostate adenocarcinoma · hormone-resistant prostate carcinoma · lymphoma · kidney cancer · leukemia · sarcoma
+4 more
· urinary bladder cancer · urothelial carcinoma · metastatic prostate carcinoma · prostate neoplasm
Investigated by: National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Eastern Cooperative Oncology Group · SWOG Cancer Research Network · Alliance for Clinical Trials in Oncology · Aventis Pharmaceuticals
+33 more
· Cancer and Leukemia Group B · Memorial Sloan Kettering Cancer Center · University of Michigan Rogel Cancer Center · Dana-Farber Cancer Institute · Fox Chase Cancer Center · Herbert Irving Comprehensive Cancer Center · NYU Langone Health · Radiation Therapy Oncology Group · SCRI Development Innovations, LLC · Sanofi · University of New Mexico · AstraZeneca · Beth Israel Deaconess Medical Center · Bristol-Myers Squibb · Celgene Corporation · Centre Hospitalier Universitaire de Besancon · Department of Veterans Affairs, New Jersey · GlaxoSmithKline · Institut de Cancérologie de Lorraine · Morton Plant Mease Health Care · NRG Oncology · National Institutes of Health Clinical Center (CC) · North Central Cancer Treatment Group · Novartis · Nuvance Health · Ortho Biotech Products, L.P. · Pfizer · St. Barnabas Medical Center · The University of Texas Health Science Center, Houston · UNICANCER · University of Medicine and Dentistry of New Jersey · University of Southern California · Walter Reed Army Medical Center

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	EMCYT	—	1981-12-24	fda.gov ↗

Trials 48 · a red edge is where a trial was stopped

today

US approved 1981

NCT02788201 · Ph 2 NCT02853071 · Ph 2 NCT02494713 · Ph 2 NCT02866955 · Ph 2 NCT00705822 · Ph 3 NCT00193271 · Ph 2 NCT00083005 · Ph 2 NCT00165399 · Ph 2 NCT00132756 · Ph 1/2 NCT00084565 · Ph 2 NCT00027859 · Ph 3 NCT00176527 · Ph 2 NCT00052845 · Ph 2 NCT00055731 · Ph 3 NCT00030654 · Ph 3 NCT00218205 · Ph 2 NCT00024167 · Ph 3 NCT00151073 · Ph 2 NCT00028769 · Ph 2 NCT00151086 · Ph 1/2 NCT00046826 · Ph 2 NCT00025194 · Ph 1/2 NCT00016107 · Ph 2 NCT00016913 · Ph 2 NCT00005847 · Ph 2 NCT00183924 · Ph 2 NCT01250717 · Ph 2 NCT00038246 · Ph 1/2 NCT00014352 · Ph 2 NCT00193193 · Ph 2 NCT00038168 · Ph 1/2 NCT00005810 · Ph 2 NCT00004054 · Ph 3 NCT00004001 · Ph 3 NCT00005627 · Ph 1 NCT00003614 · Ph 2 NCT00151060 · Ph 2 NCT00003717 · Ph 2 NCT00004105 · Ph 1/2 NCT00003584 · Ph 2 NCT00003394 · Ph 1/2 NCT00002775 · Ph 1/2 NCT00003084 · Ph 2 NCT00005048 · Ph 1 NCT00003066 · Ph 2 NCT00002855 · Ph 3 NCT00021372 · Ph 2 NCT00002721 · Ph 1

198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT00005627	Mar 1999 → Apr 2003	prostate cancer	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1	NCT00005048	Apr 1997 → Aug 2000	prostate cancer	NYU Langone Health	Completed	No outcome recorded
Phase 1	NCT00002721	Mar 1995 → Jun 2013	prostate cancer	University of New Mexico	Completed	No outcome recorded
Phase 1/28 trials
Phase 1/2	NCT00132756	Dec 2003 → ?	prostate cancer	Morton Plant Mease Health Care	Terminated	No outcome recorded
Phase 1/2	NCT00151086	Dec 2001 → Mar 2004	prostate cancer	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00025194	Jul 2001 → Jul 2006	prostate cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00038246	Oct 2000 → Feb 2004	prostate cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00038168	Jun 2000 → Jan 2003	prostate cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00004105	Sep 1998 → Apr 2003	leukemia, lymphoma, sarcoma	NYU Langone Health	Completed	No outcome recorded
Phase 1/2	NCT00003394	Apr 1998 → Apr 2003	prostate cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00002775	Feb 1998 → ?	prostate cancer	Herbert Irving Comprehensive Cancer Center	Unknown	No outcome recorded
Phase 229 trials
Phase 2	NCT02788201	Mar 2017 → Oct 2019	urinary bladder cancer, urothelial carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT02853071	Jan 2017 → Jan 2020	breast cancer	Centre Hospitalier Universitaire de Besancon	Withdrawn	No outcome recorded
Phase 2	NCT02494713	Oct 2015 → Sep 2017	prostate cancer	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 2	NCT02866955	Jun 2011 → Aug 2014	breast cancer	Institut de Cancérologie de Lorraine	Completed	No outcome recorded
Phase 2	NCT00193271	Aug 2004 → May 2007	prostate cancer	SCRI Development Innovations, LLC	Completed	No outcome recorded
Phase 2	NCT00083005	Mar 2004 → Dec 2007	prostate cancer	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 2	NCT00165399	Mar 2004 → Dec 2005	prostate adenocarcinoma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00084565	Nov 2003 → Nov 2004	prostate cancer	Fox Chase Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT00176527	Nov 2002 → Aug 2007	prostate cancer	University of Medicine and Dentistry of New Jersey	Terminated	No outcome recorded
Phase 2	NCT00052845	Nov 2002 → Jan 2006	prostate cancer	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00218205	Jul 2002 → Jun 2006	prostate cancer	Department of Veterans Affairs, New Jersey	Unknown	No outcome recorded
Phase 2	NCT00151073	Apr 2002 → Sep 2005	hormone-resistant prostate carcinoma	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
Phase 2	NCT00028769	Dec 2001 → Jun 2010	prostate cancer	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 2	NCT00046826	Sep 2001 → Jun 2007	prostate cancer	Nuvance Health	Completed	No outcome recorded
Phase 2	NCT00016107	Jun 2001 → Feb 2007	hormone-resistant prostate carcinoma, prostate adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00016913	May 2001 → Jul 2007	prostate cancer	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00005847	Apr 2001 → Jul 2004	prostate cancer	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 2	NCT00183924	Mar 2001 → Jul 2006	prostate adenocarcinoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT01250717	Jan 2001 → May 2011	prostate cancer	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 2	NCT00014352	Sep 2000 → Mar 2003	prostate cancer, thrombotic disease	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00193193	Aug 2000 → Dec 2003	prostate cancer	SCRI Development Innovations, LLC	Completed	No outcome recorded
Phase 2	NCT00005810	Mar 2000 → Dec 2003	prostate cancer	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00003614	Feb 1999 → Apr 2005	prostate cancer	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 2	NCT00151060	Dec 1998 → Nov 2004	prostate cancer	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003717	Oct 1998 → ?	prostate cancer	St. Barnabas Medical Center	Unknown	No outcome recorded
Phase 2	NCT00003584	Jul 1998 → Dec 2000	kidney cancer	University of New Mexico	Completed	No outcome recorded
Phase 2	NCT00003084	Dec 1997 → Nov 2002	prostate cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003066	Feb 1997 → ?	breast cancer	Herbert Irving Comprehensive Cancer Center	Unknown	No outcome recorded
Phase 2	NCT00021372	Feb 1996 → Sep 2006	lymphoma	Fox Chase Cancer Center	Completed	No outcome recorded

Phase 38 trials
Phase 3	NCT00705822	Aug 2006 → Jul 2009	prostate cancer	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00027859	Oct 2003 → Dec 2004	prostate cancer	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 3	NCT00055731	Nov 2002 → Dec 2010	prostate cancer	UNICANCER	Completed	No outcome recorded
Phase 3	NCT00030654	Oct 2002 → Feb 2005	prostate cancer	Radiation Therapy Oncology Group	Completed	No outcome recorded
Phase 3	NCT00024167	Apr 2002 → Sep 2014	prostate cancer	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 3	NCT00004054	Jan 2000 → Apr 2010	prostate cancer	Radiation Therapy Oncology Group	Completed	No outcome recorded
Phase 3	NCT00004001	Oct 1999 → Jul 2006	prostate cancer	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 3	NCT00002855	Aug 1996 → Jun 2005	prostate cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded

Also used as a comparator or background therapy in 3 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT00003633 Background	Aug 1998 → ?	prostate cancer	Herbert Irving Comprehensive Cancer Center	Unknown	No outcome recorded
Phase 22 trials
Phase 2	NCT02560051 Comparator	Nov 2015 → Sep 2017	prostate neoplasm	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 2	NCT00541281 Comparator	Dec 2003 → Feb 2006	hormone-resistant prostate carcinoma, metastatic prostate carcinoma	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Completed	No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 54 sources stand behind the page.

Field	Value	Cited text
Known as	estramustine	“Patients also received estramustine (140 mg p.o. three times daily on days 1-5, 8-12, and 15-19)” PMID 15671557 ↗ Jan 2005 45 “Erlotinib, Estramustine, Etoposide” NCT02788201 ↗ NCT00004001 ↗ NCT00028769 ↗ NCT00005048 ↗ NCT00003084 ↗ NCT00002721 ↗ NCT00005810 ↗ NCT00038168 ↗ NCT00132756 ↗ NCT00193271 ↗ NCT00021372 ↗ NCT00705822 ↗ NCT02866955 ↗ NCT00005847 ↗ NCT00003584 ↗ NCT00052845 ↗ NCT00083005 ↗ NCT00046826 ↗ NCT00030654 ↗ NCT01250717 ↗ NCT00151086 ↗ NCT00038246 ↗ NCT00151073 ↗ NCT00014352 ↗ NCT00024167 ↗ NCT00002775 ↗ NCT00016913 ↗ NCT00004105 ↗ NCT00165399 ↗ NCT00176527 ↗ NCT00193193 ↗ NCT00183924 ↗ NCT00055731 ↗ NCT02494713 ↗ NCT00003066 ↗ NCT02560051 ↗ NCT02853071 ↗ NCT00151060 ↗ NCT00016107 ↗ NCT00003717 ↗ NCT00003633 ↗ NCT00541281 ↗ NCT00027859 ↗ NCT00084565 ↗ NCT00003394 ↗
Known as	EMP	“with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer.” PMID 15735119 ↗ Mar 2005
Known as	estramustine phosphate	“with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer.” PMID 15735119 ↗ Mar 2005 2 “paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen deprivation therapy” PMID 18989865 ↗ Dec 2008 NCT00218205 ↗
Known as	estramustine phosphate sodium	“estramustine phosphate sodium” NCT00083005 ↗ 5 NCT00025194 ↗ NCT00004054 ↗ NCT00003614 ↗ NCT00002855 ↗ NCT00005627 ↗
Known as	NSC-89199	“Doxorubicin, DOX, NSC-123127; Estramustine, EM, NSC-89199.” NCT00002721 ↗
Action	Inhibit	“Estramustine may fight prostate cancer by reducing the production of androgens.” NCT00052845 ↗
Modality	Other / unclassified	“Estramustine and Taxotere are chemotherapy drugs” NCT00151073 ↗
Route	Oral	“oral estramustine (EM)” NCT00002721 ↗